Remodeling of calcium signaling in tumor progression by Yih-Fung Chen et al.
Chen et al. Journal of Biomedical Science 2013, 20:23
http://www.jbiomedsci.com/content/20/1/23REVIEW Open AccessRemodeling of calcium signaling in tumor
progression
Yih-Fung Chen1, Ying-Ting Chen2, Wen-Tai Chiu2,3 and Meng-Ru Shen1,4,5,6*Abstract
Intracellular Ca2+ is one of the crucial signalings that modulate various cellular functions. The dysregulation of Ca2+
homeostasis has been suggested as an important event in driving the expression of the malignant phenotypes,
such as proliferation, migration, invasion, and metastasis. Cell migration is an early prerequisite for tumor metastasis
that has a significant impact on patient prognosis. During cell migration, the exquisite spatial and temporal
organization of intracellular Ca2+ provides a rapid and robust way for the selective activation of signaling
components that play a central role in cytoskeletal reorganization, traction force generation, and focal adhesion
dynamics. A number of known molecular components involved in Ca2+ influx pathways, including stromal
interaction molecule (STIM)/Orai-mediated store-operated Ca2+ entry (SOCE) and the Ca2+-permeable transient
receptor potential (TRP) channels, have been implicated in cancer cell migration and tumor metastasis. The clinical
significance of these molecules, such as STIM proteins and the TRPM7 channel, in tumor progression and their
diagnostic and prognostic potentials have also been demonstrated in specific cancer types. In this review, we
summarize the recent advances in understanding the important roles and regulatory mechanisms of these Ca2+
influx pathways on malignant behaviors of tumor cells. The clinical implications in facilitating current diagnostic and
therapeutic procedures are also discussed.
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channelsReview
The ubiquitous second messenger Ca2+ is an important
signaling for several fundamental physiological functions,
such as cell cycle control, survival, apoptosis, migration,
and gene expressions [1]. Regulation of intracellular Ca2+
([Ca2+]i) homeostasis involves both Ca
2+ entry from the
extracellular space and Ca2+ release from the intracellular
stores, such as the endoplasmic reticulum (ER) or mito-
chondria [2]. Some human diseases have been linked
with the abnormal regulation of Ca2+ homeostasis, includ-
ing developmental disorders, hypertension, cardiovascular
disease, diabetes, Alzheimer's disease, and cancer [3,4].
Although changes in Ca2+ homeostasis may not be a neces-
sity for malignant initiation, the altered Ca2+ signalings in
cancer cells contribute to important events during tumor* Correspondence: mrshen@mail.ncku.edu.tw
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reproduction in any medium, provided the orprogression, such as proliferation, migration, invasion, and
metastasis [5,6]. Understanding the remodeling of Ca2+
homeostasis in cancer cells may thus shed a light on the
potential therapeutic targets or prognostic biomarkers. This
review focuses on the important roles and regulatory mech-
anisms of Ca2+ influx pathways in aggravating tumor malig-
nant behaviors, particularly in cellular migration and
tumor metastasis.Cell migration: a dynamic process between focal
adhesion turnover, cytoskeletal dynamics and cell
contractility
Cell migration and invasion are a prerequisite for tumor
metastasis which has a great impact on cancer patient
outcomes. The migratory ability assists cancer cells in
escaping from their primary sites of origin, and contrib-
utes to their dissemination through nearby circulations.
The spatial and temporal coordination of cell-substrate
adhesion, actin cytoskeleton, non-muscle myosin II-
mediated contraction and cell-substrate detachment aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is the structural and signaling linkage complexes be-
tween the extracellular matrix (ECM) and cytoskeleton
that are known as focal adhesions [9,10]. The speed of
the coordinated and dynamic formation and disassembly
of focal adhesions determines the efficiency of cell mi-
gration. The association between actin filaments and
myosin II forms contractile actomyosin fibers [11]. Mi-
gratory cells generate intracellular forces to support the
rear-end retraction and forward protrusion through the
myosin II-based actomyosin contractility. The transmis-
sion of myosin II-based actomyosin contraction to focal
adhesions establishes the contractile force that relocates
the cell body and contributes to cell locomotion [12].
These contractile forces are important for the regulation
of focal adhesion turnover and cytoskeletal organization,
and thus mediate the efficient cell migration.
Ca2+ signaling in cell migration
In addition to the extracellular chemoattractant stimula-
tions, cell migration depends on the spatially and tempor-
ally coordinated intracellular Ca2+ signaling [13]. During
cell migration, Ca2+ signaling has a multifunctional role in
directional sensing, cytoskeleton redistribution, traction
force generation, and relocation of focal adhesions [14].
Polarized, migrating cells exhibit a rear-to-front gradient
of [Ca2+]i, with higher concentration at the rear end of a
migrating cell, which is thought to be responsible for
rear-end retraction [15]. On the other hand, spatially and
temporally confined repetitive changes in [Ca2+]i, termed
as Ca2+ flickers or Ca2+ microdomains, are enriched near
the leading edge of migrating cells and implicated in con-
trolling cycles of lamellipodia retraction and strengthening
local adhesion to ECM [16-18]. The rear-end retraction
is supported by the processes of actomyosin contraction
and focal adhesion disassembly that are regulated by
Ca2+-dependent signalings. The myosin II-based acto-
myosin contraction is mainly mediated by myosin light-
chain (MLC) phosphorylation through the Ca2+-dependent
MLC kinase (MLCK) [19]. The disassembly of cell adhe-
sions is due to the cleavage of focal adhesion proteins, such
as integrins, talin, vinculin and focal adhesion kinase (FAK),
by the Ca2+-dependent protease, calpain [20,21]. Additional
biochemical links between [Ca2+]i and the focal adhesions
is provided by the focal adhesion-localized proline-rich
tyrosine kinase 2 (Pyk2), which requires Ca2+ for activation
[22]. The Ca2+-dependent activation of calpain and Pyk2
thus regulates multiple signaling events crucial for the focal
adhesion turnover and cell migration.
Ca2+ influx pathways in cell migration and tumor
metastasis
Transient changes in [Ca2+]i play an important role in vari-
ous cellular processes associated with cancer cell migrationand tumor metastasis [14]. The spatially-confined sus-
tained or transient increases of Ca2+ concentration can
occur in the form of waves, spikes or oscillations [23]. Such
increases occur as a result of Ca2+ entry through plasma
membrane Ca2+-permeable channels or Ca2+ mobilization
from internal stores, such as the ER, through the ryanodine
receptor (RYR) and/or the inositol-1,4,5-trisphosphate
receptor (IP3R) channels [24]. Several plasmalemmal Ca2+
channels have been suggested to play important roles in
regulating cancer cell migration and tumor metastasis, as
summarized in Table 1. The emerging role of dysregulated
mitochondrial Ca2+ homeostasis in tumorigenesis has
also received increasing attention [25-28]. The reduction of
mitochondrial Ca2+ uptake in cancer cells can decrease the
activation of the mitochondrial intrinsic apoptosis pathway,
and thus favors cancer cell survival and tumor metastasis.
This review focuses on the important role of stromal inter-
action molecule (STIM)/Orai-mediated store-operated Ca2+
entry (SOCE) and the Ca2+-permeable transient receptor
potential (TRP) channels on tumor malignant behaviors.
STIM/Orai in SOCE activation and Ca2+ homeostasis
SOCE is a predominant pathway of Ca2+ entry in non-
excitable cells, and is widely distributed in various cell
types [48]. SOCE, by definition, is activated by Ca2+ re-
lease from the internal store. SOCE-mediated Ca2+ in-
flux provides Ca2+ not only for ER store refilling, but
also for signaling purposes. As shown in Figure 1A, the
SOCE activation includes several steps: (1) Stimulation
of G protein-coupled receptors or receptor protein tyro-
sine kinases activates phospholipase C, which hydrolyzes
phosphatidylinositol bisphosphate to release the second
messenger inositol-1,4,5-trisphosphate (IP3). (2) Binding
of IP3 to IP3 receptors in the ER membrane causes a rapid
and transient Ca2+ release from ER lumen. (3) The de-
crease in ER luminal Ca2+ activates store-operated Ca2+
(SOC) channels in the plasma membrane, leading to a
sustained influx of extracellular Ca2+ across the plasma
membrane [49].
Two main molecular components have been identified
as essential for SOCE activation [50-53]: STIM molecules
as the ER Ca2+ sensors and Orai proteins as the pore-
forming subunits of the plasmalemmal SOC channel
(Figure 1B & 1C). Mammals possess three types of Orai
proteins (Orai1-3) [53,54], of which Orai1 is the most ex-
tensively characterized. Although all three Orai proteins
form functional SOC channels when co-expressed with
STIM1, they differ in tissue distribution and in the select-
ivity and conductivity for Ca2+ [54]. STIM molecules,
STIM1 and STIM2, are the single-transmembrane pro-
teins that are mainly localized in the ER membrane. As
shown in Figure 1B, the important functional domains of
STIM1 include a canonical EF hand Ca2+-binding domain
and a sterile α-motif (SAM) protein interaction domain in
Table 1 Role of plasmalemmal Ca2+ channels in cell migration and tumor metastasis
Ca2+ channel Cell type Mechanisms and effectors References
Store-dependent SOC channels
STIM1-Orai1 • Human cervical cancer SiHa and CaSki cells • Increase in EGF-stimulated cellular migration and
invasion
[29,30]
• Increase in focal adhesion dynamics through the
Ca2+-regulated protease calpain and cytoplasmic kinase Pyk2
• Upregulation of EGF-induced MLC phosphorylation and
actomyosin reorganization
• Upregulation of VEGF production
• Promotion of tumor growth and angiogenesis in a
xenograft mice model
• Human breast cancer MDA-MB-231 cells and mouse
mammary tumor 4 T1 cells
• Increase in serum-induced cellular migration and
invasion
[31]
• Increase in focal adhesion turnover rates through Ras and
Rac1
• Promotion of tumor growth and metastasis in a xenograft
mice model
STIM-Orai3 • Human breast cancer MCF7 cells (ER+ breast cancer cells) • Increase in anchorage-independent growth and Matrigel
invasion
[32,33]
• Increase in tumorigenesis in a xenograft mice model
Store-independent SOC channel
SPCA2-Orai1 • Human breast cancer MCF-7 cells • Constitutively active store-independent Ca2+ influx [34]
• Promotion of proliferation and colony formation
• Increase in tumorigenesis in a xenograft mice model
TRP channels
TRPM1 • Murine melanoma B16-F1 cells • Reduce in tumor metastasis [35,36]
TRPM7 • Human breast cancer MDA-MB-231 cells and MEF cells • Increase in cellular migration [18,37-39]
• Guidance of polarized cellular migration
• Increase in peripheral focal adhesion turnovers through
the Ca2+-regulated protease m-calpain
• Inhibition of myosin II-based cell contractility
• Increase in tumorigenesis in a xenograft mice model
• Human nasopharyngeal cancer 5-8 F and 6-10B cells • Increase in cellular migration [40]
• Human lung cancer A549 cells • Increase in EGF-stimulated cellular migration [38]
TRPM8 • Human prostate cancer PC-3 cells • Decrease in cellular migration [41,42]
• Inactivation of FAK
TRPV1 • Human hepatoblastoma HepG2 cells • Increase in HGF-stimulated cellular migration [43,44]
TRPV2 • Human prostate cancer LNCaP and PC-3 cells • Increase in cellular migration and invasion [45]
• Induction of invasive enzymes MMP-2, MMP-9 and
cathepsin B
• Increase in tumorigenesis in a xenograft mice model
TRPC6 • Human glioblastoma cells • Increase in cell proliferation through regulation of CDK1
activation and Cdc25C expression
[46,47]
• Increase in anchorage-independent growth and Matrigel
invasion
• Increase in endothelial cell tube formation
• Increase in tumorigenesis in a xenograft mice model
Cdc25C, cell division cycle 25 homolog C; CDK1, cyclin-dependent kinase 1; EGF, epidermal growth factor; ER, estrogen receptor; FAK, focal adhesion kincase;
HGF, hepatocyte growth factor; SPCA2, secretory pathway Ca2+-ATPase; MEF, mouse embryonic fibroblast; MMP, matrix metalloproteinase; Pyk2, proline-rich
tyrosine kinase 2; VEGF, vascular endothelial cell growth factor.
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Figure 1 Regulatory mechanism of [Ca2+]i homeostasis. (A) Store-operated calcium entry (SOCE) in non-excitable cells. The activation of
surface receptors stimulates phospholipase C (PLC) to increase the second messenger inositol-1,4,5-trisphosphate (IP3), which binds to the IP3
receptor in the endoplasmic reticulum (ER) membrane and causes rapid and transient Ca2+ release from the ER lumen. The decrease in ER
luminal Ca2+ results in the opening of the plasmalemmal store-operated Ca2+ (SOC) channel, leading to the elevated intracellular Ca2+ levels
([Ca2+]i). (B) Domain architecture of the ER Ca
2+ sensor stromal interaction molecule 1 (STIM1) protein. STIM1 is a single-transmembrane protein
that is mainly localized in the endoplasmic reticulum (ER). The luminal N-terminus contains a canonical EF hand motif that binds Ca2+, a hidden
EF hand that does not bind Ca2+, and a sterile α-motif (SAM) domain that is important for STIM1 oligomerization. The cytosolic C-terminus
contains the coiled-coil domains, a STIM-Orai activating region (SOAR) or CRAC activation domain (CAD), and serine or proline (S/P)-rich segments
and lysine (K)-rich clusters. The SOAR/CAD domain is essential for the gating of Orai1. The predicted protein-protein interaction domains in STIM1
include the SAM domain, coiled-coil domains, SOAR/CAD domain, S/P-rich segments and K-rich clusters. (C) Predicted topology of the
plasmalemmal SOC channel Orai1. Orai1 consists of four transmembrane domains (TM1-TM4) and intracellular N- and C-termini. It is suggested
that the TM1 lines the central pore of Orai1 channel. The short C-terminal putative coiled-coil domain is important for binding to the SOAR/CAD
domain of STIM1, and its disruption impairs STIM1-mediated activation of Orai1 channel. Hexagonal structures represent glycosyl residues
attached to an arginine (N)-linked glycosylation site (N223).
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region (SOAR), which is similar to the CRAC activation
domain (CAD), in the cytoplasmic C-terminal end [55].
The EF hand domain enables STIM1 to sense small de-
creases in ER luminal Ca2+ concentration, whereas the
SAM domain mediates the STIM1 oligomerization. As
depicted in Figure 2, once ER Ca2+ is depleted, STIM1
proteins oligomerize into multiple punctae and redistrib-
ute to the close proximity of plasma membranes, known
as the ER-plasma membrane junctions. Orai1 protein, a
four-transmembrane domain Ca2+ channel in the plasma
membrane, translocates to the STIM1-containing ER-
plasma membrane junctions following store depletion
and opens to mediate Ca2+ entry [56]. The opening of
the Orai1 Ca2+ channel is mediated by the direct physical
interaction between the cytoplasmic C-terminal coiled-
coil domain of Orai1 and the cytoplasmic C-terminal
SOAR/CAD domain of STIM1. Although STIM2 mol-
ecule exhibits significant homology in the overall structure
and basic properties with regard to STIM1, such as ER
localization, luminal Ca2+ binding and redistribution to
puncta at ER-plasma membrane junctions upon Ca2+
store depletion, its role in SOCE activation remains con-
troversial [55]. It has been recently reported that differentagonists activate different STIM proteins to sustain Ca2+
signals and downstream responses [57].
The physiological and pathological importance of SOCE
has been implicated in many diseases, especially in immune
disorders. SOCE is critical for the development and function
of regulatory T cells and the formation of “immunological
synapses” between T lymphocytes and antigen-presenting
cells [58,59]. STIM1 or Orai1-deficiency causes several auto-
immune diseases and myopathy in human subjects and
mouse models [60,61]. Mast cells lacking either STIM1 or
Orai1 exhibit defective cytokine production and release,
which jeopardize allergic responses [62,63]. During phago-
cytosis, the recruitment of STIM1 towards phagosomes is
required for the opening of phagosomal Ca2+ channels
that generates localized Ca2+ elevations to promote high-
efficiency phagocytosis [64]. In the lung, STIM1-Orai1
upregulation leads to an increase in pulmonary smooth
muscle cell proliferation and in endothelial cell migration
and vessel formation [65,66]. During lactation, the expres-
sion of Orai1 and STIM2 in mouse mammary glands is
increased, whereas STIM1 is downregulated, indicating
that Orai1-dependent SOCE may be one of the important
Ca2+ influx routes to meet Ca2+ transport demand during
lactation [67].
Figure 2 STIM1-dependent SOCE activation. STIM1 exists as the dimer maintained by the intermolecular interactions between its coiled-coil
domains in the resting state (①). Depletion of ER luminal Ca2+ causes Ca2+ dissociation from the STIM1 N-terminal canonical EF hand, leading to
STIM1 oligomerization due to the intermolecular interactions between EF-SAM domains (②). This activated STIM1 puncta interacts with the
plasma membrane (PM) by the C-terminal polybasic K-rich clusters and accumulates in the ER-PM junctions (③). Orai1 tetramers diffusing in the
PM (④) are tethered and trapped in junctions by the electrostatic interaction between CAD/SOAR domain in STIM1 and basic domains in the
C-terminus of Orai1. The formation of the active STIM1/Orai1 complex conformationally gates the opening of SOC channel Orai1, thereby
allowing Ca2+ entry (⑤). Upon store refilling, re-association of Ca2+ with STIM1 reverses EF-SAM oligomerization, causing STIM1-Orai1 uncoupling,
Orai1 deactivation and the release of resting STIM1 dimers from puncta to redistribute throughout the ER (⑥).
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adhesion turnover and actomyosin contractility
The molecular mechanisms of SOCE in regulating cancer
cell migration have been emerged from studies on breast
and cervical cancer cells [29,31]. Yang et al. provided
evidence for the role of STIM1 and Orai1 in the migration
of breast cancer cells [31]. Blocking SOCE, by a pharma-
cological inhibitor SKF96365 or by siRNA-mediated silen-
cing of STIM1 or Orai1, impaired the focal adhesion
turnover and invasive migrations of breast cancer cells.
These defects of focal adhesion turnover and cell migra-
tion could be rescued by the constitutively active forms of
the small GTPases Ras and Rac1 [29]. STIM1-dependent
Ca2+ signalings also play an important role in epidermal
growth factor (EGF)-stimulated cervical cancer cell migra-
tion [29]. EGF, an important stimulator for cancer cells
migration [68], can stimulate the aggregation and trans-
location of STIM1 towards to the Orai1-containing
regions of plasma membrane to mediate SOCE. STIM1-
dependent SOCE is necessary for the activation of
Ca2+-dependent protease calpain and tyrosine kinase
Pyk2, which regulate the focal-adhesion dynamics of
migratory cervical cancer cells. More importantly, STIM1-
dependent Ca2+ signalings control cervical cancer cell
migration by the regulation of actomyosin reorganizationin conjunction with enhanced contractile forces [30].
STIM1 silencing inhibited the recruitment and association
of active FAK and talin at focal adhesions, indicating the
blockade of force transduction from integrin signaling.
Furthermore, EGF-induced MLC phosphorylation and
actomyosin reorganization were abolished by STIM1
knockdown and SOCE inhibitors. The direct measure-
ment of cell traction forces revealed that STIM1-
dependent Ca2+ signaling regulates the traction force
generation at cell adhesions. The results from these stud-
ies suggest that STIM1-dependent Ca2+ signaling could
integrate the dynamic interactions between actomyosin
and focal adhesion to mediate efficient cell migration. The
related mechanisms at least partly involve the modulation
of focal adhesion turnover through the Ca2+-dependent
Pyk2 and the small GTPase Rac1, focal adhesion protein
cleavage through the Ca2+-dependent protease calpain,
and actomyosin formation through MLC phosphorylation
(as summarized in Figure 3). The significance of STIM1 in
cellular migration may extend beyond breast and cervical
cancer given its role in the migration and focal adhesion
turnover in hepatocarcinoma cells [69]. Targeting the mo-
lecular components of SOCE, STIM1 and Orai1, is thus a
promising approach to inhibit cancer cell migration and
tumor metastasis.
Figure 3 STIM1-mediated Ca2+ influx regulates cell migration through focal adhesion turnover and actomyosin contractility. The
dynamic interactions among cytoskeleton, non-muscle myosin II and cell-substrate adhesion regulate cell migration. The interaction between ER
Ca2+ sensor STIM1 and plasma membrane SOC channel Orai1 induces Ca2+ influx, which integrates the dynamic interactions between
actomyosin and focal adhesion (FA) to mediate efficient cell migration. STIM1/Orai1-mediated Ca2+ influx regulates actomyosin formation
through the Ca2+-dependent myosin light chain kinase (MLCK), accelerates FA turnover through the small GTPase Rac1 and the Ca2+-dependent
proline-rich tyrosine kinase 2 (Pyk2), and promotes calpain-mediated disassembly and cleavage of FA proteins.
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The functional significance of STIM1 and Orai1 in
tumor progression in vivo has been revealed in breast
and cervical cancer [29,31]. Consistent with the pro-
migratory role of STIM1 and Orai1, suppressed expres-
sion levels of STIM1 and Orai1 in highly metastatic
breast cancer cells inhibited lung metastasis after tail
vein injection in immunodeficient SCID mice, which can
be mimicked by pharmacological inhibitor SKF96365
[31]. Moreover, STIM1-dependent Ca2+ signaling plays
an important role in tumor growth and angiogenesis
in vivo [29]. Angiogenesis, the recruitment and forma-
tion of new blood vessels, is an essential step for tumor
metastasis [70]. Through these vessels, tumor cells can
exit the primary sites of origin, enter into the systemic
circulation, and disseminate to distant organs. STIM1
overexpression significantly enhanced tumor growth,
local spread and angiogenesis of human cervical cancer
xenograft in SCID mice, whereas shRNA-mediated
knockdown of STIM1 significantly decreased tumor
growth and tumor vessel numbers [29]. It is thus pro-
posed that tumor STIM1 overexpression may benefit the
locomotion and metastasis of cancer cells. Consistently,
the intraperitoneal administration of SOCE inhibitors,
such as 2-APB and SKF96365, into human cervical
cancer-bearing mice could cause tumor growth regres-
sion accompanied by the obliteration of tumor feedingvessels [29], suggesting both tumor cells and tumor ves-
sels are the possible targets by SOCE inhibition. Mech-
anistic investigations revealed that the secretion of
vascular endothelial growth factor (VEGF), a critical
stimulator for tumor angiogenesis [71], from cervical
cancer cells was dependent on their STIM1 expressions
[29]. The results from these studies demonstrate the
crucial role of STIM1-mediated Ca2+ influx in aggravat-
ing tumor development in vivo (Figure 4), especially in
tumor angiogenesis and metastasis. Blocking Orai1- and
STIM1-dependnet Ca2+ signaling is thus a potential
strategy for cancer therapy.
Tumor STIM1 protein level has diagnostic and prognostic
value
The clinical significance of SOCE in tumor progression
has been demonstrated in cervical cancer [29]. Among
71% cases of early-stage cervical cancer examined, STIM1
protein expression was upregulated in cervical cancer
tissues but rarely detected in adjacently non-cancerous
cervical epithelia. The levels of STIM1 expression in
tumor tissues were closely correlated with the primary
tumor size, an important indicator of human cervical car-
cinoma progression in vivo [73]. In addition, cervical can-
cer patients with pelvic lymph-node metastasis, which is
the primary cause of treatment failure and subsequent
death in cervical cancer patients, displayed higher STIM1
Figure 4 STIM1/Orai1-mediated Ca2+ signalings in tumor biology. Ca2+ homeostasis is remodeled in cancer cells during tumor progression,
with Ca2+ influx increasing through STIM1/Orai1upregulation. STIM1/Orai1-dependent Ca2+ signaling integrates the dynamic interactions between
actomyosin contraction and focal adhesion turnover to mediate efficient cell migration. STIM1 also influences cancer cell proliferation through
cell cycle regulators p21 and cdc25C. Additionally, STIM1-mediated SOCE plays an important role in tumor angiogenesis; one possible mechanism
involves the production of vascular endothelial growth factor (VEGF) from cancer cells, another is the cell cycle progression of vascular
endothelial cells [72]. Accordingly, STIM1/Orai1-remodeled Ca2+ homeostasis is important for aggravating tumor development in vivo.
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cantly poorer 5-year overall survival rate was also found in
primary tumors with STIM1 upregulation. Another study,
based on the microarray data analyses of 295 breast cancer
patients, also showed that transcriptionally-defined basal-
like tumors, which have a poor prognosis and lack of ef-
fective therapies [74], are characterized by high STIM1
and low STIM2 mRNA expressions [67]. An increase in
STIM1/STIM2 gene expression ratio has been associated
with reduced survival in breast cancer patients. However,
this trend of redundancy between STIM1 and STIM2 ex-
pressions was not noted in cervical cancer patients [29],
indicating the role of STIM2 in tumor biology may be
tissue- or cell-type specific. Taken together, these studies
suggest a potential role for STIM1 protein as a diagnostic
biomarker to predict the occurrence, progression or prog-
nosis of cancer patients.
SPCA2/Orai1-mediated store-independent Ca2+ influx in
breast tumorigenesis
In addition to STIM1-mediated activation of Orai1, an
entirely different signalling mechanism, in which the Ca2+
influx through Orai1 is independent of store depletion,
has recently been implicated in human breast tumorigen-
esis (Table 1) [34]. This mechanism involves the inter-
action of Orai1 with the Golgi-localized secretory pathway
Ca2+ ATPase isoform 2 (SPCA2). SPCAs, including the
ubiquitously expressed SPCA1 isoform and more re-
stricted SPCA2 isoform [75,76], are ATP-powered Ca2+pumps that transport Ca2+ into the Golgi luman for pro-
tein sorting and processing [77]. The limited distribution
of SPCA2 includes the lumenal secretory cells of the
mammary gland, where it normally functions in the regu-
lation of Golgi Ca2+ levels and is drastically upregulated
during lactation [78]. However, the contribution of SPCA2
to breast tumor progression is not through its conven-
tional role in Golgi Ca2+ sequestration. Consistent with
the overexpression of Orai1 in breast cancer [67], SPCA2
was overexpressed in human breast cancer cell lines and
human breast tumors, whereas SPCA1 levels were similar
among all cell lines examined [34]. Additionally, SPCA2 si-
lencing attenuated basal [Ca2+]i, cell proliferation, anchorage-
independent growth and mammary tumor formation in
nude mice, whereas SPCA2 overexpression increased basal
[Ca2+]i and promoted breast tumorigenicity. Surprisingly,
SPCA2 induced Ca2+ influx independently of its ATPase
function, as a SPCA2 mutant with impaired Ca2+-ATPase
activity increased basal [Ca2+]i and anchorage-independent
growth to a similar extent to that of wild-type SPCA2. The
results from immunofluorescent staining and surface
biotinylation in breast cancer cells showed that SPCA2 is
partially localized to the plasma membrane where it inter-
acts with the N-terminus of SOC channel Orai1 to elicit
the constitutive STIM1-independent Ca2+ influx. As a re-
sult, the Ca2+ dependent nuclear translocation of nuclear
factor of activated T cells (NFAT) was upregulated in
breast cancer cells. The SPCA2-Orai1 complex thus elicits
a novel type of constitutive store-independent Ca2+ signal-
ling that promotes breast tumorigenesis.
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The TRP channels are non-selective cation channels and
Ca2+ entry pathways in various non-excitable and excitable
cells [79]. The superfamily of TRP cation channels are ubi-
quitously expressed and display an extraordinary diversity
of activation mechanisms and functional properties, which
enables them to participate in various physiological and
pathological conditions, including distinguishing sensa-
tions, cell migration and cancer progression [80]. Approxi-
mately thirty TRPs have been identified to date and many
of them are considered as key players with regard to
mechanosensory signalings. Based on sequence homology
and channel function, TRP channels can be divided
into three main subfamilies: TRPC (Canonical), TRPV
(Vanilloid) and TRPM (Melastatin). Many studies have
linked specific TRP channels to cancer progression: TRPM1
in human melanoma cells [35,36], TRPV1 in human
hepatoblastoma cells [43,44], TRPV2 and TRPM8 in hu-
man prostate cancer cells [41,42,45], and TRPC6 in human
glioblastoma cells [46,47] (as summarized in Table 1). How-
ever, most of these studies are still phenomenological and
the downstream Ca2+-dependent molecules regulating cell
migration and tumor metastasis are often unknown.
TRPM7 regulates cell migration though myosin II-based
contractility
Among the various TRP cation channels, TRPM7 is the
most comprehensively studied class in the context of cell
migration. TRPM7 is a bifunctional protein composed of
a Ca2+- and Mg2+- permeable TRP channel fused to a C-
terminal α-kinase domain [81], and plays an important
role in regulating actomyosin contractility, cell adhesion
and directional migration [18,37,82]. TRPM7 can be ac-
tivated by mechanical force or PLC-activating agonists
[18]. Exposure of cells to mechanical stress leads to the
opening of the TRPM7 channel, and thereby activates
the stretched-activated Ca2+ influx at the front of mi-
grating cells [18]. The Ca2+ entry through TRPM7 at the
front of migrating cells is locally amplified by ER Ca2+
release through the IP3R, and thus generates the high
Ca2+ microdomains (Ca2+ flickers) that are required for
the guidance of directional movement. In addition,
TRPM7 is localized with a Ca2+-dependent protease m-
calpain at peripheral adhesions, where it regulates focal
adhesion assembly and turnover through m-calpain, pos-
sibly by mediating the local Ca2+ influx near peripheral
adhesions [37]. Moreover, a Ca2+- and kinase-dependent
association between TRPM7 and myosin IIA of the
actomyosin cytoskeleton occurs at the proximity of cell
adhesions [19]. The α-kinase domain of TRPM7 phos-
phorylates the myosin IIA heavy chain, and thereby leads
to the inhibition of myosin II-based cell contractility and
the remodeling of cell adhesions [82]. Taken together,
TRPM7-mediated Ca2+ flux is an important regulator fordirectional cell migration through modulating myosin II-
based cellular tension and focal adhesion dynamics.
The contributions of TRPM7 to cancer cell migration
and tumor metastasis have recently received increasing
attention [38-40]. A pro-migratory role of TRPM7 was
demonstrated in human nasopharyngeal carcinoma, in
which overexpression of TRPM7 protein or increase in
its Ca2+ channel activity significantly promoted the mi-
gration capability, whereas the interference with TRPM7
expression or activation decreased it [40]. It has also
been shown that EGF can upregulate the surface expres-
sion of TRPM7 proteins and the amplitude of TRPM7
currents, which are important for the basal and the
EGF-enhanced cell migration of human lung adenocar-
cinoma A549 cells [38]. A recent study linking TRPM7
to cell migration and tumor metastasis also suggests the
potential of TRPM7 as a strong and independent prog-
nostic marker of poor prognosis of metastatic breast
cancer [39]. In breast cancer patients, high levels of
TRPM7 mRNA expression were associated with higher
incidence of recurrence and metastasis independently of
standard clinical parameters. Moreover, TRPM7 expres-
sion was functionally required for the invasive migration
and the metastasis formation in a mouse xenograft
model of human breast cancer [39]. Mechanistic investi-
gations by siRNA-mediated TRPM7 silencing revealed
that TRPM7 regulates myosin II-based cytoskeletal con-
tractility and thereby modifies focal adhesion turnover,
cell-cell adhesions and polarized cell migration [39].
Therefore, TRPM7 might be part of a mechanosensing
complex adopted by cancer cells to drive cancer meta-
static phenotypes.Conclusions
Remodeling of Ca2+ homeostasis is an important event that
regulates cancer malignant behaviors. However, there is
as yet limited understanding of the role for specific Ca2+
signaling in controlling cancer cell migration and tumor
metastasis. Future studies could focus on the discovery of
potential agents that selectively target cancer cell-specific
or tumor vasculature-specific Ca2+ influx pathways to facili-
tate the current diagnostic and therapeutic procedures [72].Abbreviations
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